Condition: B-cell NHL · CLL · Sponsor: Fondazione Matilde Tettamanti Menotti De Marchi Onlus
This is a single arm, open-label, multi-center, phase I/II study to determine the engraftment, safety and clinical activity of allogeneic CARCIK-CD19 cells in adult and pediatric patients with relapsed/refractory mature B-cell neoplasia expected to express CD19 i.e. B-cell NHL and CLL. CARCIK-CD19 will be produced from the peripheral blood of an at least haploidentical familial donor.
This description comes directly from the study's public registry record.
Andrea Biondi, MD · +39039233 · segreteriadirezionecp@fondazionembbm.it
Alessandro Rambaldi, MD · +39035267 · ematologiasegr@asst-pg23.it
Always discuss trial participation with your own doctor first.
| Ospedale Papa Giovanni XXIII | Bergamo, BG, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05869279